INTRODUCTION
High levels of soluble phospholipase A2 (PLA2) have been detected at sites of inflammation in numerous animal models. ARDS (the adult respiratory-distress syndrome), acute pancreatitis, septic shock and inflammatory arthritis have been associated with elevated levels of endogenous secretory PLA2 Nevalainen, 1980; Vadas, 1984) .
Several studies have examined soluble PLA2s from polymorphonuclear leucocytes. Soluble enzymes stored in specific granules of polymorphs and lysosomes ofphagocytes are released into the extracellular space in response to phagocytic, antigenic or chemoattractant stimuli (Vadas & Hay, 1980; Traynor & Authii, 1981; Lanni & Becker, 1983; Balsinde, et al., 1988) . PLA2 provides substrates for the synthesis of potent mediators of inflammation, including prostaglandins, leukotrienes and the platelet-activating factor (Pruzanski & Vadas, 1991) . PLA2 is thus a key enzyme in the pathogenesis of inflammatory disease.
PLA2 purified from rabbit granulocytes has been localized by immunocytochemical methods in rabbit phagocytes (Namba et al., 1983) . The physical state of PLA2s stored in lysosomal granules (soluble or membrane-bound) still remains unclear (Franson et al., 1974 (Franson et al., , 1977 Alonso et al., 1986; GonzalesBuritica et al., 1989a,b) . Adsorption of soluble PLA2 to phospholipid membranes complicates the interpretation of subcellular localization . It has been reported that the enzyme becomes membrane-associated upon cell activation, which facilitates the hydrolysis of membrane-bound substrates (Channon & Leslie, 1990) . Comparison of the structural and functional properties of PLA2s purified from polymorphonuclear leucocytes, cell-free ascitic fluid and serum shows that all three enzymes are very closely related, which suggests that serum may be the source of PLA2 in inflammatory exudate (Wright et al., 1990; Franson et al., 1974 Franson et al., , 1978 . PLA2 has also been isolated from human synovial fluid and platelets, and the enzyme is identical in both sources (Stefanski et al., 1986; Hara et al., 1989; Seilhamer et al., 1989) .
The purpose of the present study was to isolate human asciticfluid PLA2 (a-PLA2). A polyclonal (rabbit) antiserum was also prepared, and a time-resolved fluoroimmunoassay (TR-FIA) was developed for measuring the content of a-PLA2 in various body fluids.
EXPERIMENTAL

Materials
Dextran T 500, CM-Sepharose CL 6B and activated CHSepharose 4B were purchased from Pharmacia (Uppsala, Sweden).
[14C]Oleic acid (57 mCi/mmol) and L-a-dipalmitoyl-[2-palmitoyl-9,10-3H(n)]phosphatidylcholine (50 Ci/mmol) were from NEN (Boston, MA, U.S.A.), and 1-[14C]palmitoyl-L-lyso-3-phosphatidylcholine (59 mCi/mmol) was from Amersham International (Amersham, Bucks, U.K.). Freund's adjuvant and fatty-acid-free BSA were from Sigma Chemical Co. (St. Louis, MO, U.S.A.). Calibration kits for determination of Mr values of proteins were from Pharmacia. Assay buffer and Eu-chelate for TR-FIA measurements were from Wallac (Turku, Finland), and microtitre plates were from Eflab (Helsinki, Finland).
Ascitic fluid was collected from hospitalized patients suffering from ovarian carcinoma and peritoneal carcinosis. Human pancreatic phospholipase A2 (p-PLA2) was purified as described by Eskola et al. (1983a) .
Purification of PLA2 from human ascitic fluid
Ion-exchange chromatography of cell-free ascitic fluid was performed on a CM-Sepharose CL 6B column (2.4 cm x 40 cm) equilibrated with 2.5 mM-Tris/HCI, pH 7.4, containing 0.15 MNaCl. Anionic proteins were eluted with the same buffer, and PLA2 was eluted with buffered 2 M-NaCl. The elution was monitored by the A280. PLA2-containing fractions were pooled, trifluoroacetic acid (TFA) was added to 0.1 % (v/v), and the fractions were subjected to h.p.l.c. on a reverse-phase column (Aquapore Octyl RP 300; 4.6 mm x 220 mm; Brownlee Laboratory, Santa Clara, CA, U.S.A.). The column was equilibrated with 0.1 % TFA, and PLA2 was eluted with increasing amounts of 95 % (v/v) (Patriarca et al., 1972) or a mixture of 2-[3H]palmitoyl-phosphatidylcholine and unlabelled dipalmitoyl-phosphatidylcholine as a substrate (Schaidlich et al., 1987) . 1-[14C]Palmitoyl-lysophosphatidylcholine served as a substrate in the assay for lysophospholipase activity. E. coli was labelled as described by Patriarca et al. (1972) and used in the routine method for the determination of PLA2 activity in the chromatographic steps. The reaction mixture consisted of 100 Fl of autoclaved 14C-labelled E. coli suspension (5000 c.p.m.) in 100 mM-Tris/HCl (pH 7) buffer containing 1 mM-CaC12 and 10 F1 of sample to be measured. To determine the pH-dependence of activity, 100 mM-acetate (pH 3.0-6.0), -Tris/HCI (pH 7-9) and -glycine/NaOH (pH 9-10) buffers were used. The incubation time was 30 min and temperature 37 'C. The reaction was terminated by adding 200,u1 of 2 M-HCI, followed by 200 ,ul of BSA solution (20 mg/ml). After cooling at 4 'C for 30 min, the samples were centrifuged at 9000 g for 5 min. The supernatant was mixed with 4 ml of Optiphase Hisafe II scintillation liquid (Wallac), and radioactivity was measured in a liquid-scintillation counter (1209 Rackbeta; Wallac). Enzyme activities were corrected for non-enzymic hydrolysis and expressed as percentages of the total E. coli lipid radioactivity.
Immunoreactive PLA2 was measured by TR-FIA. Microtitre plates were coated overnight with affinity-purified antiserum raised against a-PLA2 (10 Ftg/ml; 200,ul/well). The coating solution was prepared by incubating the antiserum with 3 vol. of HCl/water (154 Fu1 of 11.6 M-HCI in 50 ml of water) for 5 min and diluted to 10 ,ug/ml with 50 mM-Tris/HCl buffer (pH 7.75)/0.15 M-NaCl/0.05 % NaN3. After six washes, a-PLA2 standard or unknown sample (25 Fl) was added with 175Fu1 of assay buffer. After incubation and washing, 200Fll (1 Fug/ml) of affinity-purified antiserum labelled with Eu-chelate, as described by Eskola et al. (1983b) activity is expressed as percentage of the total E. coli lipid radioactivity.
Preparation of tissue homogenates
The homogenates of human pancreas and spleen were prepared by a method described for the purification of human p-PLA2 (Eskola et al., 1983a) . Leucocytes were separated from 40 ml of buffy coat, representing 450 ml of blood. Erythrocytes were sedimented with 1.3 % (w/v) dextran at room temperature. The leucocyte-rich supernatant was centrifuged at 300 g for 10 min. Isolated leucocytes were disrupted as described by Balsinde et al. (1988) .
RESULTS
Purification and characterization of human ascitic-fluid PLA2
As the first purification step, ascitic fluid was applied to a CMSepharose CL 6B column for ion-exchange chromatography. More than 95 % of the total protein and part of the PLA2 activity (26%) and immunoreactivity (2.5 %) were eluted in the flowthrough fraction. A single peak of PLA2 activity was eluted with buffered 2 M-NaCl (Fig. 1) . The PLA2-containing pool was further purified on a reverse-phase column h.p.l.c. The PLA2 activity was eluted as a single peak at approx. 30 % acetonitrile concentration (Fig. 2) .
The h.p.l.c. fraction was judged to be homogeneous. The apparent Mr of the enzyme was estimated to be 10000 by SDS/PAGE (Fig. 3a) and by h.p.l.c. on a TSK G 3000 gelfiltration column (results not shown). The catalytic activity of the purified a-PLA2 was optimal between pH 6 and 9. The enzyme was Ca2+-dependent (optimum at 1 mM-Ca2+). No activity was detected in the presence of 1 mM-EDTA. The positonal specificity of the enzyme was tested by using 1-[14C]palmitoyl-L-lyso-3-phosphatidylcholine as a substrate. Radioactive fatty acids were not released during the incubation.
The activity of the product increased to 260-fold that of the starting material. The final yield was about 300 ,ug of a-PLA2, representing a recovery about 15 % of total PLA2 activity ( Table   1) .
Characterization of antibody
The antibody raised against a-PLA2 was tested for specificity The antiserum revealed two major bands of apparent Mr around 67 000 and 10 000 and three minor bands of Mr over 94000, about 43000 and 30000. The antiserum detected a single protein band with purified a-PLA2 (Fig. 3) . It did not cross-react with PLA2in 10 3x Mr human pancreas or spleen homogenates as measured by TR-FIA OA (Table 2) .
Ascitic PLA2 content in body fluids as determined by TR-FIA A sandwich TR-FIA method was developed for measurement of the a-PLA2 concentration. A typical curve is shown in Fig. 4 . The minimal amount of a-PLA2 detectable with this method is approx. 6 ng/ml. The concentrations of a-PLA2 in fluids from several sources as determined by TR-FIA are given in Table 2 . The concentration of a-PLA2 in normal human serum increased after repeated freezing and thawing. The PLA2 content of fresh serum was 19 ug/ml on average, and that of frozen and thawed serum was 68,ag/ml. No difference was found in the content of a-PLA2 between plasma and serum samples from the same healthy individuals. The concentration of a-PLA2 in leucocyte homogenate was about 5 ng/ml. Leucocytes from 450 ml of blood gave in total about 40 ng of a-PLA2.
DISCUSSION
The present results show that PLA2 in the ascitic fluid of patients suffering from ovarian carcinoma and peritoneal carcinosis is a cationic protein. Table 2 . Determination of the contents of a-PLA2 and p-PLA2 in body fluids from various sources Tissue homogenates were prepared as described in the Experimental section. Protein concentrations of pancreas, spleen and leucocyte homogenates were 26, 17 and 0.15 mg/ml respectively. Concentrations of a-PLA2 and p-PLA2 were measured by TR-FIA as described in the Experimental section. Eskola et al. (1983b) . Bieber, 1978; Kondo et al., 1982) . The purified enzyme does not hydrolyse 1-acyl-lysophospholipid. In the presence of 2-[3H]-palmitoyl-phosphatidylcholine radioactivity was recovered as non-esterified fatty acids. The a-PLA2 therefore seemed specific for the fatty acid at position 2. The enzyme was purified 260-fold to apparent homogeneity as judged by SDS/PAGE. Characteristics of the purified enzyme (pH optimum, Ca2+ requirement) are similar to other non-pancreatic PLA2s purified previously (Franson et al., 1978; Forst et al., 1986; Chang et al., 1987) .
We investigated the distribution and the content of a-PLA2 in body fluids from various sources by TR-FIA. The enzyme was not found in homogenates of pancreas or spleen, but the concentrations found in normal human serum, ascitic fluid and synovial fluid were relatively high. The concentration of a-PLA2 in normal human serum is approx. 68 ,ug/ml (the present work), whereas that of p-PLA2 is 6.5 ng/ml (Eskola et al., 1983b) . Murakami et al. (1990) determined the concentration of the platelet-type PLA2 by an enzyme immunoassay in rat serum to be about 1 ug/ml. Even in acute pancreatitis the concentration of p-PLA2 increases, on average, only to 50 ng/ml (Nevalainen et al., 1985) . Obviously, the source of a-PLA2 (unknown at present) must be quite abundant.
The polyclonal antiserum raised against a-PLA2 showed specific reactivity towards its antigen, as determined by immunoblotting. Purified a-PLA2 gave a single band in the immunoblotting. Several bands were found by immunoblotting in cellfree ascitic fluid. Two major bands were of M, 10000 and around 67000, and there were three minor bands, of Mr 30000, 43000 and over 94000. These bands did not appear after immunostaining with pre-immune serum or with antiserum previously incubated with an excess of antigen. One possibility is that these proteins are isoenzymes of a-PLA2. Another explanation is that PLA2molecules aggregate in the absence of high salt concentrations (Franson et al., 1978) . High-Mr PLA2s have been purified from a macrophage cell line (Leslie et al., 1988) and from human and sheep platelets (Apitz-Castro et al., 1979; Loeb & Guss, 1986 ). PLA2 may also be associated with high-Mr proteins present in ascitic fluid.
Several mammalian non-pancreatic PLA2s have been purified. However, it is at present unclear which enzymes are relevant in inflammatory diseases. Inflammatory exudate contains at least two distinct PLA2 activities: membrane-associated and soluble. They differ in their substrate specificity (Gonzales-Buritica et al., 1989a,b; Seilhamer et al., 1989). The presence of various forms of PLA2 in inflammatory exudates raises the possibility that each may have a different function in the inflammatory process. Their cellular sources remain still uncertain. It has been suggested that platelets may be the source of PLA2 in synovial fluid and inflammatory exudate (Kramer, et al., 1989) . However, there is evidence that human platelets do not secrete PLA2 upon stimulation (Hara et al., 1989) . We have determuned the concentration of a-PLA2 in both plasma and serum samples from the same healthy individuals and found no difference. This result indicates that a-PLA2 is not released by platelets. It is well known that PLA2 is present in rabbit and human polymorphonuclear leucocytes (Elsbach et al., 1979; Forst et al., 1986; Marki & Franson, 1986; Wright et al., 1990) . On the other hand, the PLA2 activity of inflammatory exudate does not correlate with white-cell count (Pruzanski et al., 1985) . However, recently Loeser et al. (1990) reported a positive correlation between arachidonic acid release and white-cell count in synovial fluid of patients with rheumatoid arthritis. Wright et al. (1990) suggest that polymorphonuclear leucocytes might be a minor additional source of inflammatoryfluid PLA2. Our results also show that PLA2 released from leucocytes represents less than 1 % of a-PLA2 present in ascitic fluid or serum.
We have ascertained in the present paper that the PLA2 found in the ascitic fluid of patients suffering from ovarian carcinoma and peritoneal carcinosis is not of pancreatic origin.
